FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938280489> ?p ?o ?g. }

• W2938280489 endingPage "392" @default.
• W2938280489 startingPage "381" @default.
• W2938280489 abstract "Introduction: Selective inhibition of the MAPK pathway with BRAF and MEK inhibitors has emerged as a key component of the treatment of BRAF-mutant unresectable/locally advanced metastatic melanoma.Areas covered: Current data are presented on the efficacy and safety of BRAFi + MEKi combination therapy (dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib) from phase I, II, and III trials in the unresectable/locally advanced metastatic setting, as well as neoadjuvant and adjuvant applications. The theoretical basis, pre-clinical findings, clinical trial results and current ongoing clinical studies of combined BRAF/MEK inhibition with immunotherapy, also known as ‘triplet therapy,’ are also explored.Expert opinion: Combination therapy with BRAF and MEK inhibitors dramatically improves response rates, progression-free survival and overall survival in patients with BRAF-mutant metastatic melanoma compared to historical treatments such as chemotherapy. Some serious adverse effects, including cutaneous squamous cell carcinoma, are attenuated with combination therapy, while less severe and reversible effects including pyrexia, left ventricular dysfunction, and ocular events can be more common with combination therapy. Existing data are insufficient to recommend triplet therapy, or a particular treatment sequence, with respect to BRAF and MEK inhibitors and immune therapies, though results from multiple ongoing trials are anticipated.Trial registration: ClinicalTrials.gov identifier: NCT02231775.Trial registration: ClinicalTrials.gov identifier: NCT01940809.Trial registration: ClinicalTrials.gov identifier: NCT02902042.Trial registration: ClinicalTrials.gov identifier: NCT02967692.Trial registration: ClinicalTrials.gov identifier: NCT02858921.Trial registration: ClinicalTrials.gov identifier: NCT02130466.Trial registration: ClinicalTrials.gov identifier: NCT02902029.Trial registration: ClinicalTrials.gov identifier: NCT02631447.Trial registration: ClinicalTrials.gov identifier: NCT02968303.Trial registration: ClinicalTrials.gov identifier: NCT02910700.Trial registration: ClinicalTrials.gov identifier: NCT02908672.Trial registration: ClinicalTrials.gov identifier: NCT3149029." @default.
• W2938280489 created "2019-04-25" @default.
• W2938280489 creator A5003126766 @default.
• W2938280489 creator A5018317962 @default.
• W2938280489 creator A5021981756 @default.
• W2938280489 creator A5023204946 @default.
• W2938280489 creator A5025872938 @default.
• W2938280489 date "2019-04-24" @default.
• W2938280489 modified "2023-10-01" @default.
• W2938280489 title "Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings" @default.
• W2938280489 cites W1557490668 @default.
• W2938280489 cites W1950572133 @default.
• W2938280489 cites W1965370740 @default.
• W2938280489 cites W1970039331 @default.
• W2938280489 cites W1982972087 @default.
• W2938280489 cites W1986994161 @default.
• W2938280489 cites W1988379285 @default.
• W2938280489 cites W1990511191 @default.
• W2938280489 cites W1997533142 @default.
• W2938280489 cites W1997919830 @default.
• W2938280489 cites W2006741643 @default.
• W2938280489 cites W2009642188 @default.
• W2938280489 cites W2011852843 @default.
• W2938280489 cites W2024117515 @default.
• W2938280489 cites W2032211985 @default.
• W2938280489 cites W2039415986 @default.
• W2938280489 cites W2043058822 @default.
• W2938280489 cites W2050206485 @default.
• W2938280489 cites W2053473615 @default.
• W2938280489 cites W2053876196 @default.
• W2938280489 cites W2058390096 @default.
• W2938280489 cites W2071255079 @default.
• W2938280489 cites W2071525523 @default.
• W2938280489 cites W2073363047 @default.
• W2938280489 cites W2079104985 @default.
• W2938280489 cites W2080686146 @default.
• W2938280489 cites W2091100650 @default.
• W2938280489 cites W2094481139 @default.
• W2938280489 cites W2096387850 @default.
• W2938280489 cites W2097995306 @default.
• W2938280489 cites W2099044540 @default.
• W2938280489 cites W2099200814 @default.
• W2938280489 cites W2100738068 @default.
• W2938280489 cites W2103027517 @default.
• W2938280489 cites W2103675014 @default.
• W2938280489 cites W2105660237 @default.
• W2938280489 cites W2106494998 @default.
• W2938280489 cites W2106543129 @default.
• W2938280489 cites W2109387929 @default.
• W2938280489 cites W2111404068 @default.
• W2938280489 cites W2114903025 @default.
• W2938280489 cites W2116376943 @default.
• W2938280489 cites W2119233294 @default.
• W2938280489 cites W2121545342 @default.
• W2938280489 cites W2123333705 @default.
• W2938280489 cites W2123363005 @default.
• W2938280489 cites W2124662474 @default.
• W2938280489 cites W2127123639 @default.
• W2938280489 cites W2128035403 @default.
• W2938280489 cites W2128542677 @default.
• W2938280489 cites W2128758225 @default.
• W2938280489 cites W2135925159 @default.
• W2938280489 cites W2136474966 @default.
• W2938280489 cites W2136925048 @default.
• W2938280489 cites W2141674733 @default.
• W2938280489 cites W2144096834 @default.
• W2938280489 cites W2145517246 @default.
• W2938280489 cites W2149662085 @default.
• W2938280489 cites W2152897456 @default.
• W2938280489 cites W2154196978 @default.
• W2938280489 cites W2155461614 @default.
• W2938280489 cites W2156078931 @default.
• W2938280489 cites W2156266404 @default.
• W2938280489 cites W2163188200 @default.
• W2938280489 cites W2163655212 @default.
• W2938280489 cites W2164996207 @default.
• W2938280489 cites W2166262263 @default.
• W2938280489 cites W2167059308 @default.
• W2938280489 cites W2168143310 @default.
• W2938280489 cites W2171367970 @default.
• W2938280489 cites W2289851792 @default.
• W2938280489 cites W2338494814 @default.
• W2938280489 cites W2416204731 @default.
• W2938280489 cites W2469584835 @default.
• W2938280489 cites W2491982852 @default.
• W2938280489 cites W2515022710 @default.
• W2938280489 cites W2562656839 @default.
• W2938280489 cites W2611270905 @default.
• W2938280489 cites W2624834472 @default.
• W2938280489 cites W2747107882 @default.
• W2938280489 cites W2747344228 @default.
• W2938280489 cites W2752210999 @default.
• W2938280489 cites W2753432434 @default.
• W2938280489 cites W2761314488 @default.
• W2938280489 cites W2762161610 @default.
• W2938280489 cites W2762347490 @default.
• W2938280489 cites W2773258053 @default.
• W2938280489 cites W2781525129 @default.

• next